RT Journal Article
SR Electronic
T1 Oxygenated hemoglobin predicts outcome in patients with chronic lung allograft dysfunction
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA2915
DO 10.1183/13993003.congress-2021.OA2915
VO 58
IS suppl 65
A1 Kathrin Kahnert
A1 Franziska C. Trudzinski
A1 Christiane Bickert
A1 Dieter Munker
A1 Katrin Milger
A1 Michael Irlbeck
A1 Roland Tomasi
A1 Christian Schneider
A1 Sebastian Michel
A1 Felix Herth
A1 Jürgen Behr
A1 Rudolf Jörres
A1 Nikolaus Kneidinger
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/OA2915.abstract
AB Long-term outcome of lung transplant (LTx) recipients is limited by chronic allograft dysfunction (CLAD). In this setting, the amount of oxygenated haemoglobin (OxyHem, haemoglobin concentration x fractional oxygen saturation) may provide valuable information. We thus hypothesized that OxyHem predicts survival of LTx recipients at the onset of CLAD.Data from 290 LTx recipients with CLAD were analysed. After excluding patients with missing data or supplemental oxygen, the final population comprised 218 patients. The relationship between survival upon CLAD and OxyHem was analysed by Cox regression analyses and ROC curves.Among the 218 patients (102 male, 116 female), 128 (58.7%) died, median survival time after CLAD onset being 1156 days. Survival was significantly associated with type of transplantation, time to CLAD, FEV1/FEV1baseline at onset and OxyHem, which was superior to Hb or oxygen saturation. The risk for death after CLAD increased by 13% per reduction of OxyHem by 1 g/dl, and values below 11 g/dl corresponded to an 89 % increase in mortality risk.Thus, OxyHem was identified as an independent predictor of mortality after CLAD onset. Whether it is useful in supporting therapeutic decisions and potentially home-monitoring in the surveillance of lung transplant recipients has to be studied in future.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA2915.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).